Skip to main content
SpringerLink
Log in

Azithromycin Clinical Pharmacokinetics

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Azalide antibiotics, of which azithromycin is the first demonstrated, have different pharmacokinetics from other antibiotics currently used. The bioavailability of the drug is approximately 37%. Extensive and rapid distribution from serum into the intracellular compartments is followed by rapid distribution to the tissues. Tissue concentrations exceed serum concentrations by up to 100-fold following a single azithromycin 500mg dose. Concentration of the drug within phagocytes aids in its ability to combat infections. High concentrations of azithromycin are found in the tonsil, lung, prostate, lymph nodes and liver, with only small concentrations found in fat and muscle. A 500mg dose on day 1, followed by 250mg daily on days 2 to 5, has been demonstrated to maintain azithromycin concentrations at sites of infection and continues to be effective for several days after administration has ceased. The pharmacokinetics of azithromycin make it a drug with diverse therapeutic applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aronoff SC, Laurent C, Jacobs MR. In vitro activity of erythromycin, roxithromycin and CP-62,993 against common pediatric pathogens. Journal of Antimicrobial Chemotherapy 19: 275–276, 1987

    Article  PubMed  CAS  Google Scholar 

  • Coates P, Daviel R, Houston AC, Antiobus JHI, Taylor T. An open study to compare the pharmacokinetics, safety and tolerability of a multiple dose regimen of azithromycin in young and elderly volunteers. European Journal of Clinical Microbiology and Infectious Diseases 10: 850–852, 1991

    Article  CAS  Google Scholar 

  • Cooper MA, Nye K, Andrews JM, Wise R. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. Journal of Antimicrobial Chemotherapy 26: 533–538, 1990

    Article  PubMed  CAS  Google Scholar 

  • Dunkin KT, Jones S, Howard AJ. The in vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. Journal of Antimicrobial Chemotherapy 21: 405–411, 1988

    Article  PubMed  CAS  Google Scholar 

  • Earthinf C, Rendel M, Currie B, Seidlin M. Azithromycin for cerebral toxoplasmosis. Lancet 339: 437–438, 1992

    Google Scholar 

  • Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin. Journal of Antimicrobial Chemotherapy 25 (Suppl. A): 39–47, 1990

    PubMed  CAS  Google Scholar 

  • Foulds G, Chan KH, Johnson JT, Shepard RM, Johnson RB. Concentration of azithromycin in human tonsillar tissue. European Journal of Clinical Microbiology and Infectious Diseases 10: 853–856, 1991b

    Article  CAS  Google Scholar 

  • Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 25 (Suppl. A): 73–82, 1990

    PubMed  CAS  Google Scholar 

  • Foulds G, Madssen P, Cox C, Shepard R, Johnson R. Concentration of azithromycin in human prostatic tissue. European Journal of Clinical Microbiology and Infectious Diseases 10: 868–871, 1991a

    Article  CAS  Google Scholar 

  • Glaude RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanisms of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 33: 277–282, 1989

    Article  Google Scholar 

  • Harrison JD, Jones JA, Morris DL. Azithromycin levels in plasma and gastric tissue, juice and mucus. European Journal of Clinical Microbiology and Infectious Diseases 10: 862–864, 1991

    Article  CAS  Google Scholar 

  • Karma P, Pukander J, Penttila M. Azithromycin concentrations in sinus fluid and mucosa after oral administration. European Journal of Clinical Microbiology and Infectious Diseases 10: 856–859, 1991

    Article  CAS  Google Scholar 

  • Kitzis MD, Goldstein FW, Miegi M, Aca JF. In vitro activity of azithromycin against gram negative bacilli and anaerobic bacteria. Journal of Antimicrobial Chemotherapy 25 (Suppl. A): 15–18, 1990

    PubMed  CAS  Google Scholar 

  • Krohn K. Gynaecological tissue levels of azithromycin. European Journal of Clinical Microbiology and Infectious Diseases 10: 865–868, 1991

    Google Scholar 

  • Lode H. The pharmacokinetics of azithromycin and their clinical significance. European Journal of Clinical Microbiology and Infectious Diseases 10: 807–812, 1991

    Article  CAS  Google Scholar 

  • McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. European Journal of Clinical Microbiology and Infectious Diseases 10: 828–833, 1991

    Article  CAS  Google Scholar 

  • Moellering RC. Introduction: Revolutionary changes in the macrolide and azalide antibiotics. American Journal of Medicine 91 (Suppl. 3A): 1S–4S, 1991

    Article  PubMed  Google Scholar 

  • Morris DL, De Souza A, Jones JA, Morgan WE. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. European Journal of Clinical Microbiology and Infectious Diseases 10: 859–861, 1991

    Article  CAS  Google Scholar 

  • Neu HC. Clinical microbiology of azithromycin. American Journal of Medicine 91 (Suppl. 3A): 12S–18S, 1991

    Article  PubMed  CAS  Google Scholar 

  • Norrby SR. Azithromycin: an antibiotic with unusual properties. European Journal of Clinical Microbiology and Infectious Diseases 10: 805–806, 1991

    Article  Google Scholar 

  • Schentag JJ, Ballow CH. Tissue directed pharmacokinetics. American Journal of Medicine 91 (Suppl. 3A): 5S–11S, 1991

    Article  PubMed  CAS  Google Scholar 

  • Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gasev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. Journal of Antimicrobial Chemotherapy 25 (Suppl. A): 123–126, 1990

    PubMed  Google Scholar 

  • Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. Journal of Antimicrobial Chemotherapy 25 (Suppl. A): 49–60, 1990

    PubMed  CAS  Google Scholar 

  • Steingrimsson O, Olafsson O, Thorarinson A, Ryan RW, Johnson RB, et al. Azithromycin in the treatment of sexually transmitted diseases. Journal of Antimicrobial Chemotherapy 25 (Suppl. A): 109–114, 1990

    PubMed  Google Scholar 

  • Williams JD. Spectrum of activity of azithromycin. European Journal of Clinical Microbiology and Infectious Diseases 10: 813–820, 1991

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, St George Hospital, Belgrave Street, Kogarah, Sydney, New South Wales, 2217, Australia

    Nestor J. Lalak &  David L. Morris (Professor of Surgery)

Authors
  1. Nestor J. Lalak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David L. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lalak, N.J., Morris, D.L. Azithromycin Clinical Pharmacokinetics. Clin. Pharmacokinet. 25, 370–374 (1993). https://doi.org/10.2165/00003088-199325050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325050-00003

Keywords

Search

Navigation